Nixon Ronald T 4

What Happened
Ronald T. Nixon, a 10% owner of Sanara MedTech, was granted 4,154 shares of restricted common stock on 2026-06-04. The shares were issued at $0.00 (award/grant) and therefore show no cash purchase value at grant. The restricted stock vests on the earlier of the company's 2027 annual meeting or June 4, 2027, provided Mr. Nixon continues to provide certain services through that date.

Key Details

• Transaction date: 2026-06-04; Filing date: 2026-06-05 (timely filing).
• Transaction type/code: Award/Grant (A); 4,154 shares granted at $0.00 each (total $0 at grant).
• Vesting: Earlier of the 2027 annual shareholder meeting or June 4, 2027, subject to continued service.
• Shares owned after transaction: Not specified in the provided extract.
• Footnotes of note:
  • F1: Grant made under the 2024 Omnibus Long-Term Incentive Plan with the vesting terms above.
  • F2–F3: Mr. Nixon may be deemed to share voting/dispositive control over additional shares held of record by affiliated entities (CGI Cellerate RX, LLC; FA Sanara, LLC) due to his roles in related entities; those entities and Mr. Nixon disclaim beneficial ownership except to the extent of pecuniary interest.

Context
This was a compensation-related restricted stock grant, not an open-market purchase or sale. Such awards are typical for executive/owner compensation and do not directly signal a market buy or sell. As a reported 10% owner and manager of affiliated entities, Mr. Nixon is connected to additional record holdings through subsidiaries (per footnotes), which affects disclosure of shared control but does not necessarily change beneficial ownership assertions.